Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen

NEW YORK, October 7, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Theravance Inc. (NASDAQ: THRX), Synageva BioPharma Corp. (NASDAQ: GEVA), Nektar Therapeutics (NASDAQ: NKTR), Clovis Oncology, Inc. (NASDAQ: CLVS), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Theravance Inc. Research Report

On September 20, 2013, Theravance Inc. (Theravance) and GlaxoSmithKline plc (GSK) announced that the Japanese Ministry of Health, Labour and Welfare has approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma (in cases where concurrent use of inhaled corticosteroid and long-acting inhaled beta₂ agonist is required). "The approval of Relvar Ellipta will provide Japanese physicians with a new, important once-daily, inhaled treatment option for their asthma patients," said Rick E Winningham, CEO of Theravance. "This first approval of Relvar Ellipta in asthma represents yet another significant milestone in the respiratory partnership between Theravance and GSK." The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fa70_THRX]

--

Synageva BioPharma Corp. Research Report

On September 30, 2013, Synageva BioPharma Corp. (Synageva) announced the closing of a $179 million underwritten public offering of 3.2 million shares of common stock. The Company informed that this offering included 412,500 shares of common stock that were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $56.63 per share. The Full Research Report on Synageva BioPharma Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8624_GEVA]

--

Nektar Therapeutics Research Report

On September 30, 2013, Nektar Therapeutics (Nektar) reported that its partner AstraZeneca has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application for Naloxegol. Nektar informed that Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to laxatives. The Company claims that Naloxegol has the potential to be the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for patients with OIC and was developed using Nektar's oral small molecule polymer conjugate technology. The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3421_NKTR]

--

Clovis Oncology, Inc. Research Report

On September 29, 2013, Clovis Oncology, Inc. (Clovis Oncology) announced updated results from an ongoing Phase I/II monotherapy study of rucaparib, the Company's oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of ovarian cancer. Dr. Rebecca Kristeleit, Clinical Senior Lecturer and Consultant Medical Oncologist UCLH and UCL Cancer Institute in London, said, "We've seen significant clinical activity with one complete response in breast cancer and six partial responses in ovarian, breast and pancreatic cancers to date, and a disease control rate in patients with germline BRCA mutant ovarian (platinum-sensitive and platinum-resistant) cancer of 100% and 63% at 12 and 24 weeks, respectively. I am pleased to be participating in the Phase II and pivotal Phase III trials (ARIEL2 and ARIEL3) which aim to build on the clear activity of rucaparib in BRCA-mutant ovarian cancer and prospectively identify and test other genetic mutations associated with sensitivity to PARP inhibition in ovarian cancer. This approach has the potential to broaden applicability of PARP inhibitor treatment for ovarian cancer as well as other solid tumors and hopefully benefit many patients." The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/6a2a_CLVS]

--

ImmunoGen Inc. Research Report

On September 20, 2013, ImmunoGen, Inc. (ImmunoGen) announced positive regulatory decisions for Kadcyla (trastuzumab emtansine, formerly T-DM1) in both the European Union (EU) and Japan, the two largest pharmaceutical markets after the US. Kadcyla was approved for marketing in the US earlier in 2013. The EU's Committee for Medicinal Products for Human Use has recommended approval of Kadcyla for the treatment of adults with HER2-positive, inoperable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Further, the Japanese Ministry of Health, Labor and Welfare has approved Kadcyla for the treatment of inoperable or recurrent HER2-positive breast cancer based on results from a Japanese Phase II trial and the EMILIA Phase III trial. The Full Research Report on ImmunoGen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/11c8_IMGN]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner